þ T-cell functions that best correlate with CMV control were evaluated by studying the relationship between CMV infection and CMV-specific immune recovery as determined by proliferation assay and intracytoplasmic-IFNc assay. A total of 30 children (mean age: 8.30 years) who received an allogeneic hematopoietic SCT (HSCT) were included. In total, 13 recipients were seronegative before HSCT. None developed CMV infection or CMV-specific immunity. A total of 17 recipients were seropositive: (i) four patients spontaneously controlled CMV. The median of CMVspecific IFNc-secreting CD4 T cells was 9.13/ll at month 3 in these four patients and three of the four patients evidenced optimal proliferative responses since month 1; (ii) in 10 patients who received anti-CMV chemotherapy because of prolonged viremia, lower (P ¼ 0.016) IFNc responses (0.39/ll), together with delayed and/or depressed proliferative responses, were observed; (iii) finally, one patient with early CMV-associated disease had undetectable proliferative and IFNc responses until month 3. In conclusion, both intense IFNc responses and early proliferative responses seem to be associated with optimal CMV control.
Introduction
CMV infection and associated diseases are a major concern in hematopoietic SCT (HSCT). Cellular immunity reconstitution is of prime importance in fighting the virus and in ensuring subsequent protection. Yet, the cellular immune parameters that correlate with effective viral control remain to be more precisely identified. Monitoring of CMVspecific CD8
þ T-cell reconstitution has proven to be of some help in guiding clinicians in the prevention and treatment of CMV infection in immunocompromised individuals. Yet, even accurate assays that enumerate CD8 þ effector/memory T cells through IFNg secretion fail to delineate all patients at risk of CMV-associated disease. [1] [2] [3] [4] [5] Help by CD4 þ T cells is required for CMVspecific CD8
þ T cells to achieve effective viral control. 5, 6 A correlation between the presence of CMV-specific CD4 þ T cells and control of disease has been largely documented. [5] [6] [7] Moreover, a requirement for the early appearance of CD4 þ T cells for controlling CMV infection has been shown in solid organ transplantation, irrespective of the kinetics and intensity levels of CD8 þ T-cell response. 6 Considering the key correlates of CD4 þ immune cells and protection towards CMV, we designed the study to focus on the CD4 þ compartment. In recent years, intracellular IFNg induction for the detection of CMV-specific CD4 þ T cells 8 has largely replaced traditional lymphoproliferation assays 9, 10 because of the advantages of a more rapid and quantitative characterization of memory cells. More recent data, however, have suggested that more complex immune functions of memory cells must be considered. Specifically, fully functional memory CD4 þ T cells that can secrete IL-2 in addition to IFNg rather than effector/memory CD4 þ T cells that secrete IFNg alone seem to be associated with a lower incidence of disease in various infections. [11] [12] [13] [14] [15] [16] To obtain a further insight into the developmental kinetics of fully functional memory cells, in this study, we addressed the relationship between CMV control and the development of proliferative responses by CD4 þ T cells. In vitro proliferative responses to a CMV-lysate antigenic preparation were selected, instead of IL-2 secretion, for two reasons. First, the proliferation assay utilizes a smaller volume of blood, a critical factor in measuring cellular immunity in very young children and infants. Second, CMV-specific lymphoproliferation, which explores lateoccurring memory cells in primary infection with CMV, seemed indispensable for endowing a full reconstitution of CMV-specific immunity. 17, 18 The intracytoplasmic cytokine assay was simultaneously used whenever enough cells were available to enumerate IFNg-secreting CD4 þ T cells in response to the same antigenic preparation, because, solely, this specific and sensitive assay allows a clear assignment of the function to the CD4 þ subset. Finally, the intracytoplasmic cytokine assay was simultaneously used to enumerate IL-2-secreting CD4 þ T cells on rare occasions.
Materials and methods

Population
The study was conducted among 32 HSCT recipients who were sequentially recruited at the time of transplant from a single centre from January 2007 to June 2008, and were followed up for at least 3 months. Two were excluded because of early death (n ¼ 1) or early relapse (n ¼ 1) that precluded evaluation until month 3. The mean age of the 30 selected patients was 8.30 years (range: 0.73-16.25 years). Their main clinical characteristics are given in Table 1 .
Patients who underwent transplantation from a sibling donor received only CsA as GVHD prophylaxis, whereas patients who underwent transplantation from a matched unrelated donor, either 9 or 10 of 10 HLA compatible, received anti-thymocyte globulin before transplantation, and CsA plus short MTX thereafter. If patients developed GVHD, they received steroids (i.v. methylprednisolone 2 mg/kg/day for at least 5 days). Values in age-matched controls were from data of immunological investigations that were systematically carried out in an HSCT relative donor before donating (n ¼ 30; mean age: 7.13 years). This study was approved by the institutional ethics committee and an informed consent was obtained from both parents in accordance with the declaration of Helsinki.
CMV surveillance and therapy
Monitoring for CMV infection consisted of weekly qualitative PCR at least during the first 3 months after transplant. If positive, a quantitative PCR was performed. Antiviral chemotherapy was initiated if CMV DNA levels over 1000 copies/ml persisted for two consecutive samplings. Definition of CMV infections and diseases is as per Ljungman et al.
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Blood sampling Blood sampling consisted of 20 ml (10 ml in young children below 4 years of age) of peripheral venous blood drawn on acid-citrate-dextrose for functional assays at months 1 and 3 after transplant (in all patients), and also at month 6 whenever possible. At the same time, 1 ml of blood was drawn on EDTA to determine CD19 þ , CD3 þ , CD4 þ and CD8 þ absolute counts using the true count method (Becton-Dickinson, Le Pont de Claix, France), according to a standard procedure.
Enumeration of CMV-specific cytokine secreting cells CMV-specific IFNg-secreting cells were determined by flow cytometry after intracellular IFNg staining. For some patients IL-2-secreting cells were also assessed. Fresh PBMCs were isolated from whole blood by densitygradient separation (d ¼ 1.077) using UNI-SEPmaxi þ tubes (Novamed, AbCys, Paris, France). PBMCs were resuspended at a cell density of 10 6 cells per ml in RPMI 1640 medium, supplemented with 10% heat-inactivated foetal calf serum (Gibco, Paisley, Scotland). The culture medium also contains 10 IU/ml of recombinant IL-2 (Roche Diagnostics, Meylan, France), 2 mg/ml of CD28 antibodies (Beckman Coulter Company, Marseille, France) and 2 mg/ml of CD49d antibodies (BD biosciences, Le Pont de Claix, France). Secretion inhibitor, Brefeldin A 10 mg/ml (Sigma, Saint-Quentin-Fallavier, France), was added after 1 h. Unstimulated cells were used as negative controls and cells stimulated by 0.2 mg/ml of CD3 antibodies (JanssenCillag, Neuss, Germany) were used as positive control. Titrated amounts of CMV Ag (Abcys) were used for specific stimulation. This antigenic preparation was a culture lysate of CMV strain AD169. A concentration of 12.5 mg/ml was used, as it was found, in preliminary experiments, to be optimal in any immune individual. These cultures were incubated at 37 1C in a humidified 5% CO 2 atmosphere for 18 h. After fixation and permeabilization using the IntraStain Kit (Dako, Cytomation, Glostrups, Denmark), CD3-FITC, CD4-PC5 (Beckman Coulter) and IFNg-PE (BD biosciences) were incubated for 20 min at room temperature. For some patients, cells were incubated with CD3-FITC (Beckman Coulter), CD4-PerCP, IFNg-PE and IL-2-APC (BD Biosciences).
After washing, cells were analysed on a FACSCalibur instrument (Becton-Dickinson, San Jose, CA, USA) using Cell Quest Pro software (BD biosciences). Files were gated Table 1 Main patient characteristics CMV-specific immune recovery after HSCT V Guérin et al on small CD3 þ lymphocytes. A minimum of 20 000 gated events were acquired. The percentage of specific cells secreting IFNg and/or IL-2 was calculated as the percentage of cells secreting IFNg (and/or IL-2) after CMV stimulation minus the percentage of unstimulated cells secreting IFNg (medium). Results were considered as positive when they were over 0.03% and when results from stimulated cultures were at least three times over those from unstimulated cultures.
Determination of Ag-specific proliferation PBMCs were isolated on a density gradient and were resuspended at a cell density of 10 6 cells per ml in complete culture medium: RPMI 1640 medium supplemented with 10% heat-inactivated pooled human sera, 1% L-glutamine, penicillin and streptomycin (Sigma). PBMCs were plated as 10 5 cells per well each time in triplicate and were stimulated for 3 days with CD3
þ (global functional test required by the physicians) unstimulated (negative control), or stimulated by coated CD3 antibodies (Janssen-Cillag, Issy les Moulineaux, France) with CD28 antibodies at 0.6 mg/ml (positive control). The same cell preparation was cultured for 6 days in the presence of a titrated amount of CMV Ag (Abcys) at a concentration of 1.3 mg/ml, which was predetermined as optimal to detect responses in any immune individuals (test) or in unstimulated (negative control) cells.
[3H]-thymidine was added during the last 18 h of culture at 0.8 mCi/well (GE Healthcare-Aulnay Sous Bois, France). The positive controls were the same as those in 3 day cultures from the same patient and were seeded at the same time. Results are given in c.p.m. and as SI (stimulation index). C.p.m. was calculated as the c.p.m. after Ag-specific stimulation minus the c.p.m. of negative control. Stimulation index is defined as c.p.m. after Agspecific stimulation divided by c.p.m. of the negative control. SI 45 associated with c.p.m. 45000 was considered to be a positive response.
Statistical methods
Values of P were generated by Student's t-test, P-values below 0.05 were considered as significant.
Results
Patient characteristics
Patient characteristics are given in Table 1 . The great majority of patients had high-risk acute leukaemia in either first or subsequent CR with a high risk of relapse (n ¼ 24/30), and received an allogeneic BMT (n ¼ 29/30) after myeloablative conditioning regimen (all patients) and evidenced a low-grade GVHD (n ¼ 22/30). These clinical characteristics indicate a fairly homogenous group. As expected from the knowledge that R þ CMV patients are primarily exposed to the virus, 13 out of 17 R þ CMV but 0 out of 13 R À CMV patients evidenced DNAemia above the threshold of detection and/or reconstituted immunity to the virus during the first 3 months after HSCT. The median time to CMV-DNAemia was 34 days (range: 13-90 days) and the median of the maximum CMV load was 10 000 equivalent genome per ml. A CMV disease (gastritis) was diagnosed by histopathology and immunohistochemical analysis in one patient on day 34.
The R þ CMV status is associated with differences in CD8 þ but not in CD4 þ T-cell numbers All patients were valuable for B, T and NK-cell immune reconstitution from transplant to month 6. As shown in Figure 1 , no statistical differences were observed in the recovery of total B and NK cells between R À CMV and R þ CMV patients. Early recovery of NK cells led to similar values as those of age-matched control since month 3 in the two groups, whereas B cells reached suboptimal levels at month 6. The absolute counts of CD8 þ T-and of CD3 þ T-cells were higher in R þ CMV patients since month 3, whereas CD4 þ T-cell counts were similar. It is noteworthy that CD4 þ T cells remained at lower levels than those of age-matched controls (n ¼ 30) throughout the follow-up in R þ CMV and R À CMV patients as well (median: 280/ml and 1033/ml at month 6 in patients and controls, respectively; Po10 -5 ).
Development of proliferative and IFNg responses to CMV Recovery of immune functions was assessed in all patients at months 1 and 3 and, when feasible, also at month 6. The volume of blood sample was not sufficient in any patient at any time for studying both functions. All patients were therefore analysed for T-cell proliferation to CMV, whereas IFNg responses were analysed whenever enough numbers of lymphocytes were available.
As shown in Figure 2 , none of the 13 R Figure 2 ). The absolute numbers of CMV-specific IFNg-secreting CD4 þ cells reached the median intensity levels of controls at month 6 in this series, whereas at that time, they were significantly (P ¼ 0.047) lower in R À CMV patients. The frequencies of CMV-specific CD4 þ T cells in R þ CMV patients were as follows: 1.71% CD4 þ cells among total CD4 cells (range: 0.05-3.59) at month 1, 0.65% (range: 0.09-6.46) at month 3 and 0.67% (range: 0.19-1.33) at month 6. In contrast to absolute counts, these frequencies were significantly (Pp0.03) higher than in age-matched controls (median: 0.11%; range: 0.03-0.57), CMV-specific immune recovery after HSCT V Guérin et al which indicate that CMV-specific T-cell reconstitution was relatively more pronounced in magnitude than total CD4 þ T cells. During the course of the study, we added analysis of IL-2-responses in IFNg þ IL-2-costaining assays. As illustrated in Figure 3 , after gating on CD4 þ T cells, three responding populations could be observed, that is, single IFNg-secreting cells, single IL-2-secreting cells and IL-2 þ IFNg-secreting cells. IL-2 responses were observed in all patients analysed who evidenced proliferative responses. Surprisingly, defective proliferative responses could, however, be observed despite IL-2 responses in some patients primarily soon after HSCT (not shown). The mechanism involved will be addressed in ongoing studies.
Immune recovery of CMV-specific CD4
þ T cells consisted in the development of an IFNg response, followed by a second phase during which cells acquire a progressively higher capacity to proliferate and polyfunctional CD4 þ T cells can be observed in recipients with proliferative capacity Distinct kinetics of IFNg-and proliferative response development were suggested in several patients who evidenced IFNg responses, whereas proliferative responses were not yet detectable. To further document the differences in kinetics between the two functions, results on proliferative responses were plotted against IFNg responses from all samples that were simultaneously analysed for both proliferation and IFNg secretion. 
CMV-specific immune recovery after HSCT V Guérin et al
As shown in Figure 4 , the relative intensity levels of proliferative-and IFNg responses to CMV clearly depend on the time of sampling. At month 1, only one out of six samples from immune patients who were analysed for the two functions exhibited both IFNg-and proliferative responses, whereas they were 10 out of 13 at month 3, and 4 out of 5 at month 6. Altogether, these observations support a sequential recovery of IFNg responses at first and then a more progressive acquisition of proliferative responses.
Relationship between viral control and CMV-specific T-cell response development The R À CMV patients who are poorly exposed to CMV were excluded from the analysis that relates cellular immunity to virological events. Furthermore, 2 out of 17 R þ CMV patients, who did not seem to be infected as they had no CMV in the blood and did not recover immune response after transplantation, were not taken into account.
The remaining 15 patients were subsequently divided into 3 groups according to their relative capacity to control CMV. Group 1 consisted of four patients who spontaneously cleared the virus. Two of four did not exhibit a PCR-CMV positive in the blood during the first 3 months after HSCT, although they recovered cellular immunity against the virus, which indicates an optimal CMV control. The remaining two patients evidenced transient viremia and did not receive antiviral chemotherapy. In group 2, 10 patients evidenced more prolonged viremia. All received antiviral chemotherapy. Although a chemodependency was observed in one, all the 10 patients finally recovered in the absence of clinical symptoms. Group 3 consisted of the only patient with an early (within the first 3 months after HSCT) CMV-associated disease.
Details on immune development in each group are shown in Figure 5 . With regard to proliferative responses, earlier development since month 1 and higher-level intensities at months 3 and 6 of immune recovery were observed in the group of patients who spontaneously and permanently controlled the DNAemia virus. With regard to IFNg responses, higher-level intensities of CMV-specific CD4 þ T cells were also observed in patients who controlled the infection well without antiviral chemotherapy (9.13 range: 0.94-27.15 vs 0.39 range: 0.09-4.88 cells per ml, respectively) at month 3. Finally, the only patient with CMV disease (at day 34 after HSCT) developed no proliferative response and no persistent IFNg responses within the first 3 months after HSCT.
Discussion
Early studies that used IFNg secretion assays for the identification of immune parameters that should correlate with protection focused on the magnitude of responses. All converged to indicate that the lack of IFNg responses was linked to an increased risk of CMV-associated diseases in HSCT, in solid organ transplantation or in HIV infection. 15, 20, 21 In agreement, the only patient with an early CMV disease (day 34 after HSCT) in our series did not develop persistent IFNg responses to CMV within the first 3 months after HSCT. Several studies also suggested that the levels of CMV-specific CD4 þ T cells in the first 50 days after transplantation are predictive of risk of viral reactivation, 22, 23 and cell counts over 1 cell per ml at month 2 seemed to be associated with protection against future CMV reactivation. 22 Although our study was not designed to address this issue, it must be noticed that among six patients with IFNg-secreting CD4 þ T cells over 1 cell per ml of blood at month 3, recurrence of DNAemia was observed only once in two patients. In both cases, DNAemia was transient and spontaneously solved.
In this study, in contrast to other reports, we found an association between the intensity levels of IFNg responses and the capacity to spontaneously resolve infection. Indeed, a significantly (P ¼ 0.016) higher response was observed in the group of patients who spontaneously solved infections compared with that in the group of patients who were treated because of more prolonged DNAemia (median: 9.13 vs 0.39 CMV-specific CD4 þ T cells per ml). The reasons for these interlaboratory discrepancies are not clear. The use of different sources of CMV Ags for in vitro stimulation and/or differences in time to sampling after transplant might be involved. This underlines the need for an effort to standardize the methods. Regardless of the reasons, our data further support that the intensity levels of IFNg responses are important immune parameters to be considered in CMV control.
A major advancement of our work over previously published results also lies in detailed information on the kinetics of proliferative responses related to IFNg responses and to the severity of infection. Accumulating evidence challenges a concept that proliferating memory cells preferentially develop in the later stages of infection. The delay would be several months after a primary infection with CMV in healthy pregnant and non-pregnant women. 24 Our data support a delayed development of proliferative responses compared with the development of IFNg responses. Yet, CMV-specific proliferative responses could be observed as early as 1 month after HSCT in five R þ CMV paediatric patients who well controlled the virus. Pourgheysari et al. 23 also observed that early CMV-specific CD4 þ T-cell reconstitution is dominated by IFNg-secreting cells in HSCT. Normal levels of IL-2 that resume 6 months after transplantation were, however, clearly more delayed in their series than were proliferative responses in ours. The reasons for these differences are unknown. Of course, differences in experimental procedures might be involved. Another explanation should consider the dissociation between IL-2 and proliferative responses under certain circumstances. This postulate is further supported by preliminary results observed herein showing, in some patients, defective proliferative responses despite IL-2 responses. This observation suggests that CMV-specific memory CD4
þ T-cell response may be even more complex and more diverse than currently appreciated. Ongoing studies aim at systematically analysing the relationship between proliferative responses and the pattern of cytokine profiles within immune CD4 þ T cells, and address the question whether dissociated reponses are associated with CMV severity and/or susceptibility to recurrent reactivations.
In conclusion, our data further support (i) an association between undetectable IFNg responses by CD4 þ T cells and CMV disease; (ii) that the level of CMV-specific IFNg response is an important immune parameter to be considered in the determination of CMV control. More importantly (iii) they provide detailed information on the development kinetics of proliferation and reveal that this function can be observed as early as at month 1 in CMV infections that can spontaneously resolve. In theory, the early appearance of immune cells in D þ CMV /R þ CMV patients within the first month after transplant, which is associated with a good prognosis, should be donor-derived memory T cells remaining in the graft. We, however, observed that CMV-specific proliferating T cells could appear since month 1, even in one D À CMV /R þ CMV patients. In that case, proliferating memory CD4 þ T cells would derive either from the memory cells remaining in the recipient or from hematopoietic progenitors, especially in young children whose thymus exhibits a high capacity to generate naive cells. Further studies are required to clarify this point.
